CASE DETAILS: During the class period, Defendants made material misrepresentations about the safety data from its TAMARACK Phase 2 study of vobramitamab duocarmazine. On May 9, 2024, the investing public learned that the drug was significantly more dangerous than defendants had previously represented. Following this news, MGNX's stock declined 77.4% due to a drop of $11.36/share. WHAT'S NEXT? If you suffered a loss in MacroGenics during the relevant time frame, you have until September 24, 2024 to request that the Court appoint you as lead plaintiff.